Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Cladribine
Drug ID BADD_D00479
Description An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.
Indications and Usage For the treatment of active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. Also used as an alternative agent for the treatment of chronic lymphocytic leukemia (CLL), low-grade non-Hodgkin's lymphoma, and cutaneous T-cell lymphoma.
Marketing Status approved; investigational
ATC Code L01BB04; L04AA40
DrugBank ID DB00242
KEGG ID D01370
MeSH ID D017338
PubChem ID 20279
TTD Drug ID D05GJW
NDC Product Code 42658-010; 12502-5406; 0143-9871; 44087-4000; 54893-0115; 76055-0051; 63323-140; 59605-3006; 65129-1260; 76055-0052; 12502-4912; 58623-0037
UNII 47M74X9YT5
Synonyms Cladribine | 2-Chlorodeoxyadenosine | 2-Chloro-2'-deoxyadenosine | 2'-Deoxy-2-chloroadenosine | Leustatin
Chemical Information
Molecular Formula C10H12ClN5O3
CAS Registry Number 4291-63-8
SMILES C1C(C(OC1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
General physical health deterioration08.01.03.0180.000566%Not Available
Quadriparesis17.01.04.012--Not Available
Balance disorder08.01.03.081; 17.02.02.0070.000596%Not Available
Idiosyncratic drug reaction08.06.01.0020.000336%Not Available
Contusion15.03.05.007; 24.07.06.001; 23.03.11.002; 12.01.06.001--
Deep vein thrombosis24.01.02.0030.000382%Not Available
Central nervous system lesion17.02.10.0110.000306%Not Available
Systemic inflammatory response syndrome24.06.03.008; 10.02.01.008; 08.01.05.0050.000153%Not Available
Lymphatic disorder01.09.01.003--Not Available
Musculoskeletal stiffness15.03.05.027--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Catheter site cellulitis08.02.02.011; 12.07.02.011; 23.11.02.003; 11.02.01.030--Not Available
Transaminases increased13.03.04.036--Not Available
Infusion site reaction12.07.05.006; 08.02.05.005--Not Available
Haemorrhage24.07.01.002--Not Available
Postmenopausal haemorrhage24.07.03.002; 21.02.01.002--Not Available
Cognitive disorder19.21.02.001; 17.03.03.0030.000229%
Lung neoplasm malignant16.19.02.001; 22.08.01.0010.000153%Not Available
Enteritis infectious07.19.01.009; 11.01.07.016--
Angiopathy24.03.02.007--Not Available
Metastases to central nervous system17.02.10.013; 16.22.02.0040.000153%Not Available
Urine output13.13.03.003--Not Available
Neurological symptom17.02.05.0100.000153%Not Available
Prostate cancer21.04.02.002; 16.25.01.0010.000306%Not Available
Bacterial infection11.02.01.005--Not Available
Cardiac disorder02.11.01.003--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Haematotoxicity12.03.01.025; 01.05.01.0070.000153%Not Available
Infarction24.04.02.017--Not Available
Infestation23.11.01.002; 11.09.01.001--Not Available
The 10th Page    First    Pre   10 11 12    Next   Last    Total 12 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene